Biomarker-Driven Lung Cancer | Clinical

Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC

April 13, 2021

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

Subbiah Explores Treatment of Non–Small Cell Lung Cancer With a KIF5B-RET Fusion

April 09, 2021

Vivek Subbiah, MD, explored the treatment options for RET-fusion positive non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

FDA Grants Fast Track Designation to Poziotinib for Previously Treated HER2 exon 20-Positive NSCLC

March 12, 2021

The FDA has granted a fast-track designation to the tyrosine kinase inhibitor, poziotinib for the treatment of previously treated patients with non-small cell lung cancer whose tumors harbor a HER2 exon 20 mutation.

FDA Grants Sotorasib a Priority Review for KRAS G12C+ Advanced NSCLC

February 17, 2021

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.

Trastuzumab Deruxtecan Leads to Durable Responses in HER2-Mutant NSCLC

February 04, 2021

Trastuzumab deruxtecan induced a high objective response rate and durable responses among patients with HER2-mutant non–small cell lung cancer in a cohort of the phase 2 DESTINY Lung-01 trial, according to interim findings presented during the 2020 World Conference on Lung Cancer Singapore.

Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer Therapies

February 03, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

FDA Grants Accelerated Approval to Tepotinib for METex14+ NSCLC

February 03, 2021

The FDA has granted an accelerated approval to tepotinib for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a MET exon 14 skipping alteration.

Larotrectinib Shows Activity in Lung Cancer Harboring NTRK Gene Fusions

February 02, 2021

Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

Repotrectinib Demonstrates Early Clinical Activity in ROS1+ Metastatic NSCLC

January 31, 2021

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.

Tepotinib Induces Durable Responses in MET exon 14 Skipping NSCLC

January 31, 2021

In the phase 3 VISION study, treatment with the MET inhibitor, tepotinib showed durable clinical activity as treatment of patients with MET exon 14 skipping non‒small cell lung cancer.